U.S. markets open in 6 hours 21 minutes
  • S&P Futures

    4,537.75
    -33.50 (-0.73%)
     
  • Dow Futures

    35,045.00
    -214.00 (-0.61%)
     
  • Nasdaq Futures

    15,064.00
    -142.00 (-0.93%)
     
  • Russell 2000 Futures

    2,072.00
    -20.10 (-0.96%)
     
  • Crude Oil

    86.03
    +0.60 (+0.70%)
     
  • Gold

    1,811.40
    -1.00 (-0.06%)
     
  • Silver

    23.59
    +0.10 (+0.44%)
     
  • EUR/USD

    1.1335
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.8650
    0.0000 (0.00%)
     
  • Vix

    22.79
    +3.60 (+18.76%)
     
  • GBP/USD

    1.3595
    -0.0004 (-0.03%)
     
  • USD/JPY

    114.4030
    -0.1820 (-0.16%)
     
  • BTC-USD

    41,286.68
    -740.98 (-1.76%)
     
  • CMC Crypto 200

    1,171.01
    +161.63 (+16.01%)
     
  • FTSE 100

    7,563.55
    0.00 (0.00%)
     
  • Nikkei 225

    27,467.23
    -790.02 (-2.80%)
     

Altimmune to Present at Upcoming Investor and Scientific Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following conferences:

  • Piper Sandler 33rd Annual Virtual Healthcare Conference
    November 29-December 2, 2021
    Webcast available now

  • 5th Annual NASH Summit 2021
    November 30, 2021
    9:00 am Eastern Time

  • 4th Annual Evercore ISI HealthCONx Conference
    December 2, 2021
    10:55 am Eastern Time

Presentation materials, including webcast links to the Piper Sandler and Evercore ISI presentations, will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Altimmune Investor & Media Contact:

Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com